Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · May 29, 2024

Efficacy and Safety of Pamrevlumab for the Treatment of Patients With Idiopathic Pulmonary Fibrosis

JAMA: The Journal of the American Medical Association


Additional Info

JAMA: The Journal of the American Medical Association
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
JAMA 2024 May 19;[EPub Ahead of Print], G Raghu, L Richeldi, ER Fernández Pérez, MC De Salvo, RS Silva, JW Song, T Ogura, ZJ Xu, EA Belloli, X Zhang, LL Seid, L Poole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading